Point and Counterpoint: Polatuzumab Vedotin in the Front-Line Therapy for Diffuse Large B- Cell Lymphoma

Authors

Colin Thomas, Thomas Jefferson UniversityFollow
Sameep Thapa, Thomas Jefferson University
Connor McLaughlin, Thomas Jefferson University
Molly Halloran, Thomas Jefferson University
Porcu Pierluigi, Thomas Jefferson University

Document Type

Article

Publication Date

1-4-2023

Comments

This article is the author's final published version in Frontiers in Oncology, Volume 12, Article number 1098375.

The published version is available at https://doi.org/10.3389/fonc.2022.1098375. Copyright © 2023 Thomas, Thapa, McLaughlin, Halloran and Porcu.

Recommended Citation

Thomas, Colin; Thapa, Sameep; McLaughlin, Connor; Halloran, Molly; and Pierluigi, Porcu, "Point and Counterpoint: Polatuzumab Vedotin in the Front-Line Therapy for Diffuse Large B- Cell Lymphoma" (2023). Department of Medical Oncology Faculty Papers. Paper 227.
https://jdc.jefferson.edu/medoncfp/227

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Language

English